Way Towards New Life

Disorders Medications

Alleviare promptly facilitates Indian patients and physicians under Named Patient Programs (NPP) to access imported authorized medicines that are not locally available to them.

Get access to an unapproved drug for personal use.

Here is a list of some of the  Disorders Medications for which we currently have a NPP in place. If you are a patient or  healthcare professional, please click below on each to access details and information.

ZAVESCA (miglustat) capsules

Zavesca is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mild/moderate type 1 Gaucher disease

ORKAMBI (lumacaftor/ivacaftor) Tablets

Orkambi tablets are indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the cystic fibrosis

INCRELEX (mecasermin [rDNA origin] injection)

Increlex is used to treat growth failure in children whose bodies do not make enough IGF-1.

CARBAGLU (carglumic acid) tablets

Carbaglu is used to treat hyperammonemia (HYE-per-AM-moe-NEE-mee-a), a urea cycle disorder caused by lack of a certain liver enzyme.

CERDELGA (eliglustat) capsules

CERDELGA is a prescription medicine used for the long-term treatment of Gaucher disease type 1 (GD1) in adults

CYSTAGON 50 mg hard capsules

CYSTAGON is a brand-name prescription drug that’s FDA-approved to treat nephropathic (kidney) cystinosis.

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

Query Form

We would love to speak with you.
Feel free to reach out using the below details.

Access Unauthorized Medicines In India Under NPP.

What is Named-patient access programme (NPP)?

Named-patient basis access can also refer to a medicine for a specific patient or patients that is not (yet) authorised and available to them in their own country. Such medicine should or must (depending on legislation) be authorised in at least one country, from which it can be imported into the patient’s country under a Named-patient access programme (NPP).

These may be medicines that are:

  • Authorised but not yet available to be prescribed in the patient’s country.
  • Authorised and available in one country but not authorised and available in the patient’s country.
  • Discontinued in the patient’s country but not in another country.
  • In shortage in the patient’s country but not in another country.

Antibiotic

Arthritis

Diabetes

Genetics

Disorders

Hepatitis C

Hematologic Cancers

HIV/AIDS

Immunological Disorders

Liver Disease

Multiple Sclerosis

Nerver Disease

Oncology

Parkinson's Disease

Rare Disease

Soft Tissue Sarcoma

Transplant

Specialty Drugs

Get Access to an Unapproved Drug

Get access to an unapproved drug for personal use to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners. Alleviare provides only information & in any way, does not lay any claim on these brand names &/or trademarks.